All In Biotech

NDA 205488 · Acerus

Natesto

Testosterone · Nasal · Androgen

Last checked: Nov 19, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

May 28, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

728

173 Phase 3, 64 recruiting

FAERS reports

19,198

10,945 serious, 780 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 22, 2025.

1. INDICATIONS AND USAGE Natesto is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of Natesto in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. Safety and efficacy of Natesto in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Natesto is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired) ( 1 ) Limitations of use: Safety and efficacy of Natesto in men with "age-related hypogonadism" have not been established ( 1 ). Safety and efficacy of Natesto in males less than 18 years old have not been established. ( 1 , 8.4 )

Mechanism: Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, alterations in body musculature, and fat distribution. Testosterone and DHT are necessary for the normal development of secondary sex characteristics....

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NATESTO · TESTOSTERONE 5.5MG/0.122GM ACTUATION · GEL, METERED, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Testosterone" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,489
  • off label use1,238
  • fatigue1,186
  • nausea862
  • headache788
  • pain777
  • diarrhoea630
  • anxiety614
  • asthenia599
  • arthralgia598
  • dizziness596
  • dyspnoea552

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004169
2005126
2006139
2007156
2008188
2009248
2010307
2011334
2012875
2013367
2014556
20151,113
20161,060
2017984
20181,193
20191,247
20201,199
20211,219
20221,422
20231,553
20241,642
20251,729
20261,372

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Natesto (Testosterone)

2024 spending

$490K

Beneficiaries

160

634 claims

Per beneficiary

$3,060

$38.41 per unit

View as table
YearSpending
2020$107,433
2021$446,123
2022$616,094
2023$586,651
2024$489,543

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,506 on PubMed

Sponsor: Acerus

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.